MCRB Stock Price Seres Therapeutics Inc Stock Quote U.S.: Nasdaq

MCRB Stock Price Seres Therapeutics Inc Stock Quote U.S.: Nasdaq


Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile. By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. One share of MCRB stock can currently be purchased for approximately $5.89. Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat’s FREE daily newsletter.

The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share . It can also be calculated by dividing the company’s Market Cap by the Net Profit. Intraday Data provided by FACTSET and subject to terms of use.

Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference

The number of analysts that have assigned MCRB a recommendation rating is 7. Out of them, 0 rate it a Hold, while 6 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst have tagged Seres Therapeutics Inc. as Underweight, while 1 advise Sell. Analysts have rated the stock Overweight, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares. Seres Therapeutics Inc., whose market valuation is $707.29 million at the time of this writing, is expected to release its quarterly earnings report May 02, 2023 – May 08, 2023. Investors’ optimism about the company’s current quarter earnings report is understandable.

Seres Therapeutics, Inc. (MCRB) Stock Price Today, Quote & News – Seeking Alpha

Seres Therapeutics, Inc. (MCRB) Stock Price Today, Quote & News.

Posted: Sat, 04 Jul 2015 07:57:01 GMT [source]

The estimates for the next what are the various kinds of investments sales put growth at 7,850.70%. Currently, the analyst consensus on Seres Therapeutics is a Strong Buy with an average price target of $16.00, representing a 196.85% upside. In a report released today, Jefferies also maintained a Buy rating on the stock with a $10.00 price target. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 0, whereas 1 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company. Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $6 million.


In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Its lead product candidate, SER-109, is designed to reduce further recurrence of CDI, a debilitating infection of the colon, in patients who have received antibiotic therapy for recurrent CDI by… Seres Therapeutics is a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome.


In the past week, MCRB stock has gone down by 0.00%, with a monthly gain of 6.98% and a quarterly surge of 5.00%. The volatility ratio for the week is 7.55%, and the volatility levels for the last 30 days are 6.64% for Seres Therapeutics Inc. The simple moving average for the last 20 days is 0.52% for MCRB stock, with a simple moving average of 0.20% for the last 200 days. Real-time analyst ratings, insider transactions, earnings data, and more.

MCRB Seres Therapeutics, Inc.Stock Price & Overview

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. Seres Therapeutics has a short interest ratio (“days to cover”) of 10.5, which indicates bearish sentiment. 7.38% of the outstanding shares of Seres Therapeutics have been sold short. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations.

  • Not all coins provided by Apex Crypto LLC are available to New York residents.
  • They are trying to find them, count their potential and bring them to their clients.
  • The P/E ratio of Seres Therapeutics is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
  • Real-time analyst ratings, insider transactions, earnings data, and more.
  • When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company. Inc. shares dropped 18.6% in heavy Monday morning trade after the company released results from an early-stage trial testing its microbiome therapy in ulcerative colitis. Shares of Seres Therapeutics Inc. jumped 14.2% in premarket trading on Tuesday after the company shared data from a Phase 3 open-label study that confirmed the safety and efficacy of its experimental C. Apex Crypto is not a registered broker-dealer or FINRA member and your cryptocurrency holdings are not FDIC or SIPC insured. Please ensure that you fully understand the risks involved before trading. Not all coins provided by Apex Crypto LLC are available to New York residents. Please visit /cryptocurrency to see a list of crypto available to trade.

If you’re looking for stocks that are quantitatively similar to SERES THERAPEUTICS INC, a group of peers worth examining would be CRBU, CRDF, CRIS, BCDA, and GWH. George Budwell has no position in any of the stocks mentioned. The one minor drawback is that Seres has a co-commercialization agreement in place with Nestlé Health Science. As a result, the biotech will have to share profits from SER-109’s sales on a 50/50 basis.

5 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Seres Therapeutics in the last year. The consensus among Wall Street research analysts is that investors should “buy” MCRB shares. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.

moving average

Barchart is committed to ensuring digital accessibility for individuals with disabilities. We are continuously working to improve our web experience, and encourage users to Contact Us for feedback and accommodation requests. Live educational sessions using site features to explore today’s markets. Realtime quote and/or trades are not sourced from all markets. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. According to 13 stock analysts, the average 12-month stock price forecast for MCRB stock is $11.22, which predicts an increase of 91.79%. Seres Therapeutics saw its shares surge in the last session with trading volume being higher than average.

ABEO, VXRT, and ARWR are the stocks whose asset turnover ratios are most correlated with MCRB. Value is the dimension where MCRB ranks best; there it ranks ahead of 51.14% of US stocks. We have 9 different ratings for every stock to help you appreciate its future potential. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.

Seres Therapeutics has received a 71.59% net impact score from Upright. Seres Therapeutics has only been the subject of 3 research reports in the past 90 days. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. No content on the Webull Financial LLC website shall be considered as a recommendation or solicitation for the purchase or sale of securities, options, or other investment products.

Seres Therapeutics Inc. is expected to release its next quarterly earnings report between May 02 and May 08. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment. predicts future values using technical analysis of a large number of analytical parameters. MCRB stock returns are also predicted based on historical data. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

  • Since 1988 it has more than doubled the S&P 500 with an average gain of +24.52% per year.
  • On the other hand, the S&P 500 Index was up 1.44% in the last trading session while the Dow Jones Industrial closed the session higher at 1.26%.
  • With 11.99 million shares estimated at $73.5 million under it, the former controlled 9.62% of total outstanding shares.
  • Seres Therapeutics has a short interest ratio (“days to cover”) of 10.5, which indicates bearish sentiment.

Shares of Seres Therapeutics Inc. were down 4.9% in trading on Friday, the day after the company said it plans to jointly commercialize an experimental C. Seres Therapeutics reports 2022 revenue $7.13M, consensus $10.7M Seres reported a net loss of $250.2M for the full year of 2022, as compared to a net… U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Tuesday.

Share this post

Leave a Reply